Specifications Table

Subject area
Pharmaceutical Sciences More specific subject area
Bioavailability and Bioequivalence
Type of data Data collected for the Reference formulation could be managed with the objective of comparing its performance in different populations.
Development of in vitro-in vivo correlations. Efavirenz is classified as Class II drug in the Biopharmaceutical Classification System (BCS), its oral absorption is limited by its dissolution. Appropriate in vitro assays could help to explain and predict dosage bioavailability.
Data
In this article, raw pharmacokinetic data obtained in an efavirenz average bioequivalence study carried out on 14 healthy subjects is presented. Venous plasma efavirenz concentrations were obtained after a 600 mg oral dose of a local brand (Test) and the Reference, Stocrin (Merck Sharp & Dohme).
Experimental design, materials and methods
A randomized two-treatment, two-period, two-sequence, single-dose crossover study with a washout period of 28 days was performed for bioequivalence evaluation of Test formulation. Sixteen healthy Caucasian subjects were initially recruited, 8 males and 8 females. Dose (600 mg) was administered at night (9:00 p.m.) two hours after the intake of a standardized dinner. Blood samples were obtained up to 96 h post-dosing. Efavirenz concentrations were measured in venous plasma by high performance liquid chromatography with UV detection at 205 nm (HPLC-UV), using a validated analytical method with a lower limit of quantification of 50 ng/mL. Detailed information regarding this method was previously described [1] . The study protocol followed the tenets of the Declaration of Helsinki adopted by the World Medical Association in 1964 and its successive amendments, being previously approved by the Institutional Ethics Review Committee of the Faculty of Chemistry -Universidad de la República. All volunteers received a leaflet with study details and efavirenz information and signed a consent form before their entry to the study. Table 1 summarizes the demographic characteristics of participating volunteers, along with the assigned sequence of product administration. Fourteen volunteers finished the study. Subject 16 did not show up the first day of the study. Subject 11 presented rash after administration of Test formulation. Fortunately, both individuals belonged to different sequence of administration, and so replacement was not necessary to maintain the crossover balanced. Pharmacokinetic data of efavirenz after single oral dose of Test and Reference is presented in Figs. 1 and 2 . For subject 11, only Test data is available. Individual efavirenz plasma concentration from both formulations could be retrieved from a previously published article [2] .
